Tecartus (brexucabtagene autoleucel), an autologous, anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, was approved for adult patients 18 years of age and older with relapsed or refractory ...

The agency states that the letters “notify manufacturers of each such licensed product to update the package insert to include available information ... Carvykti, Kymriah, Tecartus, and Yescarta. 1 ...

In the poster being presented, patients treated with the pivotal dose of Tecartus in the pooled analysis Phase 1 and 2 (n=78), the median follow-up time was 53.6 months (range 44.7-82.3 ...

Kite, a Gilead Sciences Inc (NASDAQ: GILD) company, announced the three-year follow-up results from the pivotal ZUMA-3 study of the CAR T-cell therapy Tecartus (brexucabtagene autoleucel).

--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced that the European Commission has granted conditional marketing authorization for Tecartus™ (autologous, anti-CD19 ...

CHMP backed the CAR T cell therapy for the treatment of mantle cell lymphoma back in October Kite, a Gilead company, has announced that its chimeric antigen receptor (CAR) T cell therapy Tecartus has ...